<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506662</url>
  </required_header>
  <id_info>
    <org_study_id>NN304-1808</org_study_id>
    <secondary_id>2006-006589-41</secondary_id>
    <nct_id>NCT00506662</nct_id>
  </id_info>
  <brief_title>Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes</brief_title>
  <acronym>3L</acronym>
  <official_title>The Effect of Insulin Detemir on Glucose Control in Ageing Subjects With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to compare insulin detemir once
      daily to NPH insulin once daily as measured by blood sugar control in ageing subjects with
      type 2 diabetes naive to previous insulin therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Novo Nordisk has decided to discontinue the trial as it will not be possible to recruit the
      required number of patients. The discontinuation is based on an analysis of the significant
      delay in recruitment of patients which is likely to have a negative impact on the validity of
      the trial.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycosylated Haemoglobin (HbA1c) at Month 7</measure>
    <time_frame>week 0, month 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Haemoglobin (HbA1c) at Month 4</measure>
    <time_frame>week 0, month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Fasting Plasma Glucose (FPG) at Month 7</measure>
    <time_frame>week 0, month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Fasting Plasma Glucose (FPG) at Month 4</measure>
    <time_frame>week 0, month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Pre-lunch Plasma Glucose at Month 7</measure>
    <time_frame>week 0, month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Pre-lunch Plasma Glucose at Month 4</measure>
    <time_frame>week 0, month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Pre-dinner Plasma Glucose at Month 7</measure>
    <time_frame>week 0, month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Pre-dinner Plasma Glucose at Month 4</measure>
    <time_frame>week 0, month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight at Month 7</measure>
    <time_frame>week 0, month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight at Month 4</measure>
    <time_frame>week 0, month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Total Hypoglycaemic Episodes, Month 1</measure>
    <time_frame>weeks -2-0, month 1</time_frame>
    <description>Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Total Hypoglycaemic Episodes, Months 2-4</measure>
    <time_frame>weeks -2-0, months 2-4</time_frame>
    <description>Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Total Hypoglycaemic Episodes, Months 5-7</measure>
    <time_frame>weeks -2-0, months 5-7</time_frame>
    <description>Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin detemir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individually adjusted dose of insulin detemir once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin NPH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individually adjusted dose of insulin NPH once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
    <description>Treat-to-target, s.c. (under the skin) injection, once daily</description>
    <arm_group_label>Insulin detemir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin NPH</intervention_name>
    <description>Treat-to-target, s.c. (under the skin) injection, once daily</description>
    <arm_group_label>Insulin NPH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Insulin naive

          -  Treatment with oral anti-diabetic drugs (OADs) for at least 3 months and not achieving
             therapeutic targets

          -  HbA1c between 8% - 10.5%

        Exclusion Criteria:

          -  Secondary diabetes, MODY (Maturity Onset Diabetes of the Young)

          -  Previous treatment with insulin (except for short-term treatment with insulin for
             intercurrent illness as judged by the Investigator)

          -  Proliferative retinopathy, maculopathy requiring treatment,

          -  Hypoglycaemia unawareness as judged by the Investigator, recurrent major hypoglycaemia

          -  End stage liver disease (increased liver enzymes 4 fold), end stage renal disease
             assessed by MDRD (Modification of Diet in Renal Disease) less than 30 ml/min or
             dialysed patient, acute heart failure, any acute cardiovascular event or
             cerebrovascular event less than 6 months

          -  Acute disease with poor prognosis

          -  History of alcoholism, drug abuse, or psychiatric disease or personality disorders
             likely to invalidate voluntary consent or to prevent good compliance with the trial
             protocol

          -  Mental incapacity, unwillingness or language barrier precluding adequate understanding
             or co-operation (patients having a score of less than 15 in a previous MMSE
             (Mini-Mental State Examination) in the last six months) and any conditions as judged
             by the investigator

          -  Legal incapacity or limited legal capacity (patients under guardianship or
             curatorship)

          -  Concomitant medication for Alzheimers treatment (Memantine, Anticholinesterasique
             treatment)

          -  Participation in another clinical trial less than one month before inclusion in this
             trial

          -  Illness requiring repeated hospitalisation

          -  Known or suspected allergy to the insulin or any compositional component

          -  Anticipated change or new use in concomitant medication known to interfere with
             glucose metabolism, such as systemic corticotherapy more than 5 mg/day (prednisone)

          -  Any other condition that the Investigator feels would interfere with trial
             participation or evaluation of results

          -  Terminal illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Paris La DÃ©fense</city>
        <zip>92936</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2007</study_first_submitted>
  <study_first_submitted_qc>July 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>October 19, 2010</results_first_submitted>
  <results_first_submitted_qc>October 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2010</results_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 57 centres in 2 countries: France (35) and United Kingdom (22)</recruitment_details>
      <pre_assignment_details>Subjects in the trial were patients with type 2 diabetes being treated with oral anti-diabetic drug (OAD) therapy(ies) for at least 3 months prior to the trial and considered to benefit from insulin treatment. The randomisation target for this trial was 286.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Detemir</title>
          <description>Individually adjusted dose of insulin detemir once daily</description>
        </group>
        <group group_id="P2">
          <title>Insulin NPH</title>
          <description>Individually adjusted dose of insulin NPH once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial terminated</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not recorded</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Detemir</title>
          <description>Individually adjusted dose of insulin detemir once daily</description>
        </group>
        <group group_id="B2">
          <title>Insulin NPH</title>
          <description>Individually adjusted dose of insulin NPH once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.6" spread="5.5"/>
                    <measurement group_id="B2" value="76.1" spread="4.9"/>
                    <measurement group_id="B3" value="76.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="4.6"/>
                    <measurement group_id="B2" value="29.8" spread="5.5"/>
                    <measurement group_id="B3" value="29.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <description>Number of years since diagnosis</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="10.3"/>
                    <measurement group_id="B2" value="15.2" spread="9.4"/>
                    <measurement group_id="B3" value="14.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Haemoglobin (HbA1c)</title>
          <units>percentage of total haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.26" spread="0.87"/>
                    <measurement group_id="B2" value="9.12" spread="0.78"/>
                    <measurement group_id="B3" value="9.19" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.4" spread="15.9"/>
                    <measurement group_id="B2" value="80.4" spread="16.4"/>
                    <measurement group_id="B3" value="79.0" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glycosylated Haemoglobin (HbA1c) at Month 7</title>
        <time_frame>week 0, month 7</time_frame>
        <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Haemoglobin (HbA1c) at Month 7</title>
          <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycosylated Haemoglobin (HbA1c) at Month 4</title>
        <time_frame>week 0, month 4</time_frame>
        <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Haemoglobin (HbA1c) at Month 4</title>
          <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Fasting Plasma Glucose (FPG) at Month 7</title>
        <time_frame>week 0, month 7</time_frame>
        <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Fasting Plasma Glucose (FPG) at Month 7</title>
          <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Fasting Plasma Glucose (FPG) at Month 4</title>
        <time_frame>week 0, month 4</time_frame>
        <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Fasting Plasma Glucose (FPG) at Month 4</title>
          <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Pre-lunch Plasma Glucose at Month 7</title>
        <time_frame>week 0, month 7</time_frame>
        <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Pre-lunch Plasma Glucose at Month 7</title>
          <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Pre-lunch Plasma Glucose at Month 4</title>
        <time_frame>week 0, month 4</time_frame>
        <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Pre-lunch Plasma Glucose at Month 4</title>
          <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Pre-dinner Plasma Glucose at Month 7</title>
        <time_frame>week 0, month 7</time_frame>
        <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Pre-dinner Plasma Glucose at Month 7</title>
          <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Pre-dinner Plasma Glucose at Month 4</title>
        <time_frame>week 0, month 4</time_frame>
        <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Pre-dinner Plasma Glucose at Month 4</title>
          <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight at Month 7</title>
        <time_frame>week 0, month 7</time_frame>
        <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight at Month 7</title>
          <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight at Month 4</title>
        <time_frame>week 0, month 4</time_frame>
        <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight at Month 4</title>
          <population>Due to the recruitment issue, the trial has been prematurely interrupted and the final number of patients does not allow any efficacy analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Total Hypoglycaemic Episodes, Month 1</title>
        <description>Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period.</description>
        <time_frame>weeks -2-0, month 1</time_frame>
        <population>The safety analysis set is all patients who had been exposed to at least one dose of the trial product, and had hypoglycaemia data available at both endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Total Hypoglycaemic Episodes, Month 1</title>
          <description>Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period.</description>
          <population>The safety analysis set is all patients who had been exposed to at least one dose of the trial product, and had hypoglycaemia data available at both endpoints.</population>
          <units>episodes per week by visit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (week -2 to week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.179"/>
                    <measurement group_id="O2" value="0.073" spread="0.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (weeks 1-4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.097"/>
                    <measurement group_id="O2" value="0.120" spread="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference (month 1-screening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" spread="0.209"/>
                    <measurement group_id="O2" value="0.047" spread="0.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Total Hypoglycaemic Episodes, Months 2-4</title>
        <description>Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period.</description>
        <time_frame>weeks -2-0, months 2-4</time_frame>
        <population>The safety analysis set is all patients who had been exposed to at least one dose of the trial product, and had hypoglycaemia data available at both endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Total Hypoglycaemic Episodes, Months 2-4</title>
          <description>Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period.</description>
          <population>The safety analysis set is all patients who had been exposed to at least one dose of the trial product, and had hypoglycaemia data available at both endpoints.</population>
          <units>episodes per week by visit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (week -2 to week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.179"/>
                    <measurement group_id="O2" value="0.076" spread="0.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Months 2-4 (weeks 5-16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread="0.051"/>
                    <measurement group_id="O2" value="0.072" spread="0.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference (months 2-4 - screening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.024" spread="0.177"/>
                    <measurement group_id="O2" value="-0.004" spread="0.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Total Hypoglycaemic Episodes, Months 5-7</title>
        <description>Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period.</description>
        <time_frame>weeks -2-0, months 5-7</time_frame>
        <population>The safety analysis set is all patients who had been exposed to at least one dose of the trial product, and had hypoglycaemia data available at both endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>Individually adjusted dose of insulin detemir once daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin NPH</title>
            <description>Individually adjusted dose of insulin NPH once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Total Hypoglycaemic Episodes, Months 5-7</title>
          <description>Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period.</description>
          <population>The safety analysis set is all patients who had been exposed to at least one dose of the trial product, and had hypoglycaemia data available at both endpoints.</population>
          <units>episodes per week by visit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (week -2 to week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.179"/>
                    <measurement group_id="O2" value="0.058" spread="0.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Months 5-7 (weeks 17-28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.078"/>
                    <measurement group_id="O2" value="0.041" spread="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference (months 5-7 - screening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" spread="0.131"/>
                    <measurement group_id="O2" value="-0.017" spread="0.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were collected from July 2007 to December 2008.</time_frame>
      <desc>The safety analysis set is all patients who had been exposed to at least one dose of the trial products.</desc>
      <group_list>
        <group group_id="E1">
          <title>Insulin Detemir</title>
          <description>Individually adjusted dose of insulin detemir once daily</description>
        </group>
        <group group_id="E2">
          <title>Insulin NPH</title>
          <description>Individually adjusted dose of insulin NPH once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Steering Committee has the right to publish the entire results of the trial. Any such scientific paper, presentation, communication, or other information concerning the investigation described in this protocol, must be approved by the Steering Committee, and copies submitted in writing to Novo Nordisk prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial terminated prematurely due to low recruitment, and thus it was not possible to assess efficacy in this trial due to the small number of patients in each treatment group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

